Comparative Pharmacology
Head-to-head clinical analysis: ANTIVERT versus DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIVERT versus DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE.
ANTIVERT vs DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antivert (meclizine) is a piperazine H1 histamine receptor antagonist with central anticholinergic and sedative properties. It suppresses the chemoreceptor trigger zone and labyrinthine apparatus, reducing vestibular stimulation and vertigo.
Doxylamine succinate is a histamine H1 receptor antagonist with sedative properties; pyridoxine hydrochloride is a vitamin B6 derivative that acts as a coenzyme in amino acid, carbohydrate, and lipid metabolism. The combination is believed to reduce nausea and vomiting through central anticholinergic effects and pyridoxine supplementation.
25-100 mg orally daily in divided doses 2-4 times daily; maximum 400 mg/day.
1 tablet (doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg) orally twice daily (morning and evening), increased to three times daily if needed (one tablet in the morning, one in the afternoon, and two at bedtime). Maximum: 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 35–50 hours in adults; prolonged in renal impairment.
Doxylamine: terminal half-life 10-12 hours; steady state reached in 3-4 days. Pyridoxine: half-life 15-20 days for body stores, but plasma half-life of pyridoxal phosphate ~15-30 minutes.
Primarily renal (urine) as unchanged drug and metabolites; biliary excretion is minimal. Approximately 80% excreted unchanged in urine.
Doxylamine: ~60% renal as unchanged drug and metabolites; Pyridoxine: primarily renal as 4-pyridoxic acid and other metabolites. Up to 70% of pyridoxine metabolites excreted in urine within 24 hours.
Category C
Category C
Antiemetic
Antiemetic